Search | Page 7 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. CD34+ Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation for Non-Malignant Disease

    ... versus host disease, to evaluate incidence of primary and secondary graft rejection, to assess event free survival and overall survival, ... myelodysplastic syndromes (MDS) Gender:  Female ...

    Clinical Trial last updated 06/13/2016 - 2:06pm.

  2. Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia

    ... myelodysplastic syndromes (MDS) Phase:  Phase 1 ... or high risk mutations by FISH eg MLL, FLT-3 + Secondary AML, or A white blood cell count of > 50 x10^9/L ...

    Clinical Trial last updated 06/13/2016 - 3:31pm.

  3. AML Therapy With Irradiated Allogeneic Cells

    ... myelodysplastic syndromes (MDS) Associated Drug(s):  ... =< 1.5 mg/dl Any organ dysfunction thought to be secondary to disease will be considered separately and the patient will be ...

    Clinical Trial last updated 06/13/2016 - 3:14pm.

  4. Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies (AB-CliniMACs)

    ... myelodysplastic syndromes (MDS) Phase:  Phase 2 ... Leukemias/lymphomas Acute myeloid leukemia, primary or secondary Disease status: remission or <10% bone marrow blasts ...

    Clinical Trial last updated 06/06/2016 - 3:10pm.

  5. Prior allogeneic transplant Karnofsky Performance Score < 70% Active central nervous system (CNS) involvement by malignant cells Patients with uncontrolled bacterial, viral or fungal infections (currently taking medication and with progre

    ... myelodysplastic syndromes (MDS) Phase:  Phase 3 ... de novo AML First or subsequent relapse of AML Secondary AML Treatment with institutional standard AML therapy in those ...

    Clinical Trial last updated 06/06/2016 - 2:05pm.

  6. Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies (AB-CliniMACs)

    ... myelodysplastic syndromes (MDS) Gender:  Female ... Leukemias/lymphomas Acute myeloid leukemia, primary or secondary Disease status: remission or <10% bone marrow blasts ...

    Clinical Trial last updated 06/03/2016 - 2:45pm.

  7. StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies

    ... myelodysplastic syndromes (MDS) Associated Drug(s):  ... institutional criteria. Any second or subsequent CR. Secondary AML with prior malignancy that has been in remission for at least 12 ...

    Clinical Trial last updated 06/03/2016 - 2:37pm.

  8. A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib

    ... myelodysplastic syndromes (MDS) Phase:  Phase 1 ... but potential risk for adverse events in nursing infants secondary to treatment of the mother with ruxolitinib, breastfeeding should be ...

    Clinical Trial last updated 06/06/2016 - 2:32pm.

  9. Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

    ... in attacking cancer cells in patients with leukemia, MDS, lymphoma, Hodgkin disease, or MM, after they have received an ... or are not in a complete response at day 28 can receive secondary therapy. Drug: Methylprednisolone 1.6 mg/kg per day by vein ...

    Clinical Trial last updated 06/06/2016 - 12:41pm.

  10. Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

    ... myelodysplastic syndromes (MDS) Associated Drug(s):  ... period, and then resume prior medications. Patients with secondary acute myeloid leukemia arising from myeloproliferative disease, ...

    Clinical Trial last updated 06/06/2016 - 1:59pm.